Aspire Biopharma Holdings Inc (ASBP)
Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company listed on the NASDAQ under the ticker ASBP. The company is focused on developing and commercializing sublingual drug-delivery technology designed to enable faster absorption and novel formulations for a range of therapeutic and consumer-health applications in the United States. Its lead product is Instaprin, a soluble, pH-neutral, fast-acting aspirin product intended for cardiology-related emergencies and pain management. Aspire Biopharma is also developing additional sublingual formulations, including products related to sleep support, vitamins, testosterone, semaglutide, anti-nausea treatment, antipsychotic therapy, erectile dysfunction, seizure medication, caffeine, and other drug classes. Founded in 2021 and based in Estero, Florida, the company remains in an early development phase.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ASBP
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.7x
|
2.2x
|
249.3x
|
8.523 M
|
4.255 M
|
15.0%
|
94.0%
|
-6.3
|
—
|
52.8%
|
